Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. - Wikidata - awgldk - TriplyDB

Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

http://www.wikidata.org/entity/Q35724900

about

Inflammation, immunity, and hypertensive end-organ damage Discovery and characterization of olokizumab Suppression of autoimmune retinal inflammation by an antiangiogenic drug Life-threatening complications of adult-onset Still's disease.Idiopathic inflammatory myopathies.Biologic therapy for autoimmune diseases: an update.Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab Current and future treatments for Behçet's uveitis: road to remission.Diagnosing and treating psoriatic arthritis: an update.A new alternative therapy in dermatology: tocilizumab.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Affibody molecules as engineered protein drugs.Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies.Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance.The in vitro and in vivo anti-inflammatory activities of alphitonin-4-O-β-D-glucopyranoside.

P2860

Q26827525-D3BF69CC-A372-441C-BA7B-758C8944F0D0 Q27682535-309C2AA7-A4D2-4364-A0FC-07A5EF364033 Q28533918-E3F74E1D-BACA-446A-ADBC-51944779C095 Q33412732-4ED20E8C-43D9-4641-916B-C5BC8A687EBF Q33924451-D2FDFD12-88B4-4D0E-A5FF-9B41CD3BD035 Q34655597-C83A92C1-2DFA-47D0-A764-7E20BE5FAC99 Q35982627-BAA10232-451E-41DC-96EC-79DFD433820A Q38111308-303B023D-D213-4CA9-AA58-302D5FDEF708 Q38165235-C1AB64D4-CB49-4563-BA0B-27F31CC61277 Q38507301-926B6062-AB6F-4EC3-A76F-1EFA9FC50966 Q39100810-3E1CB3E9-BBB8-48D3-8AF9-C08990FBCF9D Q39197528-5738133C-A761-405A-B104-B11E51162C0D Q42547820-46FB94EF-E753-4269-B22B-8491566281BB Q47159877-F55E9409-AD4C-453D-8CC8-F308E5522E39 Q50123729-D6190CF1-BBF5-42B8-B253-496862FF6C36

P2860

Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

http://www.wikidata.org/entity/Q35724900

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Tocilizumab for the treatment ...... ectives and future directions.

@ast

Tocilizumab for the treatment ...... ectives and future directions.

@en

type

label

Tocilizumab for the treatment ...... ectives and future directions.

@ast

Tocilizumab for the treatment ...... ectives and future directions.

@en

prefLabel

Tocilizumab for the treatment ...... ectives and future directions.

@ast

Tocilizumab for the treatment ...... ectives and future directions.

@en

P1433

Q35724900-FD5D045F-F882-41E3-9E8C-77E3F4FD87D0

P1476

Q35724900-89EA6048-87BA-4306-BC3C-08208F02E13A

P2093

Q35724900-4A1790BC-8583-4EC1-A471-9F91545474D9

Q35724900-87D00D52-259E-44EA-BAF7-9A590C5DBF2B

P2860

Q35724900-03C35C13-EAD2-41AB-A6AB-D9033827449B

Q35724900-03DA807F-C8B1-4C3A-974F-247C1431B16B

Q35724900-0B3E8F83-C5F9-4D6B-9B7D-C1F4115B6369

Q35724900-0E9EE5B4-D088-4134-A94D-3368544C5A7E

Q35724900-1242EB36-4EB7-4692-ADDD-4367471F6D1A

Q35724900-1628AAB4-A67C-4D5B-8B4D-CE31BBA869F7

Q35724900-182C6216-F20D-4570-95A4-1ECDA01DC969

Q35724900-19445268-F86E-4098-A0D2-C6F5D4F3EC56

Q35724900-1C13AEB0-5C46-4617-8703-24BB5D025788

Q35724900-1D362896-DEAC-43FE-A85C-628013586928

P304

Q35724900-C24408C4-011D-4BBF-8C1C-EFC852DBEECA

P31

Q35724900-50630A42-8AC6-4AAA-A9B1-20DB2ABB5493

P356

Q35724900-E62DD80C-2442-4350-83F1-C8404F6C7F15

P478

Q35724900-ABA2D8FB-C235-4DD0-955B-325881C5CFDD

P577

Q35724900-85553B5A-0836-4BA7-8CD2-6FEEA0C795B9

P5875

Q35724900-E4DFDEE6-3DAB-40B1-9353-FFBD742F13A4

P698

Q35724900-F83E0669-DCE2-4B80-986B-E616337B779B

P932

Q35724900-0C8AAC5F-DD02-4561-B935-3D88E5062AD6

P356

P1433

International journal of rheumatology

P1476

Tocilizumab for the treatment ...... ectives and future directions.

@en

P2093

Atsushi Ogata

http://www.w3.org/2001/XMLSchema#string

Toshio Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

Tocilizumab for rheumatoid arthritis

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130

Molecular cloning and expression of an IL-6 signal transducer, gp130

Rationale for interleukin-6 blockade in systemic lupus erythematosus

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

IL-17 and Th17 Cells

Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

P304

946048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/946048

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221815753

http://www.w3.org/2001/XMLSchema#string

P698

22315615

http://www.w3.org/2001/XMLSchema#string

P932

3270395

http://www.w3.org/2001/XMLSchema#string